Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) released its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, Zacks reports. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.
Cumberland Pharmaceuticals Stock Performance
CPIX traded up $0.91 during trading on Tuesday, reaching $6.05. 400,017 shares of the company were exchanged, compared to its average volume of 849,868. Cumberland Pharmaceuticals has a 52 week low of $1.04 and a 52 week high of $7.19. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The firm has a 50 day moving average of $3.45 and a 200 day moving average of $2.10. The stock has a market cap of $84.95 million, a P/E ratio of -7.86 and a beta of 0.12.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on Cumberland Pharmaceuticals in a report on Friday, February 14th. They issued a “hold” rating for the company.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Featured Stories
- Five stocks we like better than Cumberland Pharmaceuticals
- Differences Between Momentum Investing and Long Term Investing
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Stock Market Sectors: What Are They and How Many Are There?
- Tesla Stock: Finding a Bottom May Take Time
- 3 Fintech Stocks With Good 2021 Prospects
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
